Evidence mapPaperPMID 39337557Full record

ArticleInternational journal of molecular sciences2024

Strongly ROS-Correlated, Time-Dependent, and Selective Antiproliferative Effects of Synthesized Nano Vesicles on BRAF Mutant Melanoma Cells and Their Hyaluronic Acid-Based Hydrogel Formulation.

Silvana Alfei, Guendalina Zuccari, Constantinos M Athanassopoulos, Cinzia Domenicotti, Barbara Marengo

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Silvana AlfeiDepartment of Pharmacy, University of Genoa, Viale Cembrano, 16148 Genoa, Italy.ORCID 0000-0002-4630-4371
Guendalina ZuccariDepartment of Pharmacy, University of Genoa, Viale Cembrano, 16148 Genoa, Italy.ORCID 0000-0002-9868-6199
Constantinos M AthanassopoulosDepartment of Chemistry, University of Patras, University Campus Rio Achaias, 26504 Patras, Greece.ORCID 0000-0002-7549-1911
Cinzia DomenicottiDepartment of Experimental Medicine (DIMES), University of Genova, Via Alberti L.B., 16132 Genoa, Italy.ORCID 0000-0002-5003-7333
Barbara MarengoDepartment of Experimental Medicine (DIMES), University of Genova, Via Alberti L.B., 16132 Genoa, Italy.ORCID 0000-0003-3056-6569

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cutaneous metastatic melanoma (CMM) is the most aggressive form of skin cancer with a poor prognosis. Drug-induced secondary tumorigenesis and the emergency of drug resistance worsen an already worrying scenario, thus rendering urgent the development of new treatments not dealing with mutable cellular processes. Triphenyl phosphonium salts (TPPSs), in addiction to acting as cytoplasmic membrane disruptors, are reported to be mitochondria-targeting compounds, exerting anticancer effects mainly by damaging their membranes and causing depolarization, impairing mitochondria functions and their DNA, triggering oxidative stress (OS), and priming primarily apoptotic cell death. TPP-based bola amphiphiles are capable of self-forming nanoparticles (NPs) with enhanced biological properties, as commonly observed for nanomaterials. Already employed in several other biomedical applications, the per se selective potent antibacterial effects of a TPP bola amphiphile have only recently been demonstrated on 50 multidrug resistant (MDR) clinical superbugs, as well as its exceptional and selective anticancer properties on sensitive and MDR neuroblastoma cells. Here, aiming at finding new molecules possibly developable as new treatments for counteracting CMM, the effects of this TPP-based bola amphiphile (BPPB) have been investigated against two BRAF mutants CMM cell lines (MeOV and MeTRAV) with excellent results (even IC

Indexed as

Cell ProliferationHyaluronic AcidHydrogelsMelanomaProto-Oncogene Proteins B-rafReactive Oxygen SpeciesAntineoplastic AgentsCell Line, TumorHumansMutationNanoparticlesSkin NeoplasmsAntineoplastic AgentsBRAF protein, humanHyaluronic AcidHydrogelsProto-Oncogene Proteins B-rafReactive Oxygen Speciesbiodegradabilitycutaneous metastatic melanoma (CMM)cytotoxicity studieshigh porosityhigh swellinghydrogel formulationlow hemolytic effectsmitochondria-targeting moleculesnanosized bola amphiphiles vesiclestriphenyl phosphonium (TPP) groups

Identifiers

PMID39337557
PMCPMC11432396

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.